Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer02:18

Cancer

55.2K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
55.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Universal paratope-epitope interaction patterns in antibody-antigen structures.

Protein science : a publication of the Protein Society·2025
Same author

Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer.

Science advances·2025
Same author

Phage display enables machine learning discovery of cancer antigen-specific TCRs.

Science advances·2025
Same author

Preclinical model for evaluating human TCRs against chimeric syngeneic tumors.

Journal for immunotherapy of cancer·2025
Same author

Convergent inducers and effectors of T cell paralysis in the tumour microenvironment.

Nature reviews. Cancer·2024
Same author

Predicting Antigen-Specificities of Orphan T Cell Receptors from Cancer Patients with TCRpcDist.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2024

Related Experiment Video

Updated: Mar 4, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Swiss-PO 2025: Advancing Cancer Mutation and Structural Analysis for Precision Oncology With the Latest Release.

Fanny S Krebs1,2, Olivier Michielin2,3, Vincent Zoete1,2

  • 1Computer-aided Molecular Engineering, Department of Oncology, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.

JCO Precision Oncology
|March 2, 2026
PubMed
Summary

The Swiss-PO platform now integrates extensive oncogenomic data and analytical tools to aid in interpreting cancer-driving gene mutations. This enhanced resource supports precision oncology research and clinical decision-making for cancer variants.

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.3K
Exploring Caspase Mutations and Post-Translational Modification by Molecular Modeling Approaches
05:56

Exploring Caspase Mutations and Post-Translational Modification by Molecular Modeling Approaches

Published on: October 13, 2022

1.9K

Related Experiment Videos

Last Updated: Mar 4, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.3K
Exploring Caspase Mutations and Post-Translational Modification by Molecular Modeling Approaches
05:56

Exploring Caspase Mutations and Post-Translational Modification by Molecular Modeling Approaches

Published on: October 13, 2022

1.9K

Area of Science:

  • Oncology
  • Bioinformatics
  • Genomics

Background:

  • Precision oncology is rapidly identifying new oncodriver genes and variants.
  • This leads to an increase in mutations with unknown functional impact.
  • There is a growing need for advanced molecular modeling tools for variant interpretation.

Purpose of the Study:

  • To expand and redesign the Swiss-PO platform.
  • To integrate large-scale oncogenomic data with structure- and sequence-based analytical tools.
  • To support variant interpretation in clinical and research settings.

Main Methods:

  • Integrated oncodriver gene data, multiple sequence alignment (MSA), and 3D structure prediction/visualization.
  • Developed modules for BRAF kinase mutation classification and protein-ligand interactions.
  • Unified external database integration for multidimensional analysis.

Main Results:

  • The updated Swiss-PO platform includes data for ~1,500 oncodriver genes, >3 million mutations, >26,000 3D structures, >4,000 MSAs, and >200,000 ligands.
  • Incorporated a BRAF kinase mutation class predictor for therapeutic decision-making.
  • Established Swiss-PO as a comprehensive resource for precision oncology.

Conclusions:

  • Enhanced Swiss-PO serves as a powerful resource for interpreting cancer-associated mutations.
  • It aids oncologists, bioinformaticians, and molecular biologists in advancing precision medicine.
  • The platform is accessible at Swiss-PO.